Consistently, our study experimentally validated that Tregs inhibit CD8+ T-cell activity in ovarian cancer, and the observed differentiation trajectories suggest that the balance between proliferative and regulatory CD4+ T-cell states may modulate CD8+ T-cell function. This evidence concerns the gene CD8A and ovarian carcinoma.